Transaction expected to increase annual revenues by 15-20%

交易预计将使年收入增加15-20%

Acquisition to boost overall profitability

收购以提高整体盈利能力

Transaction expected to close by end of Q2-24

交易预计在第2-24季度结束

BOUCHERVILLE, Québec, May 06, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) ('the Company' or 'LSL Pharma'), a Canadian integrated pharmaceutical company, is pleased to announce that it has entered into a binding Letter of Intent ('LOI') to acquire profitable privately held, Quebec-based competing contract drug manufacturer ('CDMO') specialized in the formulation, production, and marketing of natural products ('Target Co') .

加拿大综合制药公司LSL PHARMA GROUP INC.（TSXV:LSL）（“该公司”或“LSL PHARMA”）很高兴地宣布，它已经签署了一份具有约束力的意向书（“LOI”），以收购盈利的私人控股、魁北克竞争合同药物制造商（“CDMO”），该制造商专门从事天然产品的配方、生产和营销（“Target Co”）。

Target Co. and its shareholders are at arm’s length from LSL Pharma..

Target Co.及其股东与LSL Pharma保持一定距离。。

The $2.5 million purchase price, to be paid in cash only, will be funded by the proceeds from the recently completed private placements, includes a fully operational manufacturing plant. The share purchase transaction is expected to increase LSL Group’s revenues by 15-20% on an annual basis. LSL Pharma anticipates closing the transaction by the end of Q2-2024.

250万美元的收购价格仅以现金支付，将由最近完成的私人配售收益提供资金，其中包括一家全面运营的制造厂。股票购买交易预计将使LSL集团的收入每年增加15-20%。LSL Pharma预计在2024年第二季度结束交易。

Upon signing of the LOI, LSL Pharma was required to make a non-refundable payment of $100,000..

签署意向书后，LSL Pharma被要求支付100000美元的不可退还款项。。

Target Co. is based in the province of Quebec and will be integrated into LSL Laboratory CDMO activities. Target Co. manufactures a range of natural products in liquid, powder, as well as in capsule forms which are sold under its own brands or as under private labels.

Target Co.位于魁北克省，将被纳入LSL实验室CDMO活动。Target Co.生产一系列液体、粉末和胶囊形式的天然产品，这些产品以自有品牌或私人标签销售。

'This accretive transaction constitutes the first step in executing our growth strategy by expanding our CDMO operations, manufacturing capabilities and customer base,' said François Roberge, President and Chief Executive Officer of LSL Pharma. 'Target Co. is a profitable company with well-established brand names and an excellent reputation as a contract manufacturer.

LSL Pharma总裁兼首席执行官弗朗索瓦·罗伯格（FrançoisRoberge）说，这项增值交易是通过扩大CDMO运营、制造能力和客户基础来执行我们增长战略的第一步Target Co.是一家盈利的公司，拥有良好的品牌和良好的合同制造商声誉。

Its product offering, combined with that of our LSL Laboratory subsidiary, will allow us to significantly expand our presence in the fast-growing natural health products sector. We expect this transaction to generate important synergies with our existing operations as well as leveraging our head office infrastructure', added Mr.

它的产品供应，加上我们的LSL实验室子公司的产品供应，将使我们能够大大扩大我们在快速增长的天然保健品领域的业务。我们希望这项交易能够与我们现有的运营产生重要的协同作用，并利用我们的总部基础设施”。

Roberge..

罗伯吉。

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

关于前瞻性陈述的注意事项

This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as 'may', 'will', 'expect', 'intend', 'estimate', 'continue' or similar expressions.

本新闻稿可能包含适用的加拿大证券立法所定义的前瞻性声明。前瞻性陈述通常可以通过使用前瞻性术语来识别，例如“可能”、“将”、“预期”、“打算”、“估计”、“继续”或类似的表达。

Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements.

前瞻性陈述基于许多假设，并受到各种已知和未知风险和不确定性的影响，其中许多风险和不确定性超出了公司的控制或预测能力，可能导致实际结果或表现与此类前瞻性陈述中明示或暗示的结果或表现存在重大差异。

These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change, and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents..

这些风险和不确定性包括但不限于公司向加拿大证券监管机构提交的文件中确定的风险和不确定性，如立法或监管发展、竞争加剧、技术变革和一般经济状况。本文所作的所有前瞻性声明应与此类文件一起阅读。。

Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements.

提醒读者不要过度依赖前瞻性陈述。不能保证前瞻性声明中提及的任何事件会发生，如果发生，公司的实际结果、业绩或成就可能与前瞻性声明中明示或暗示的结果、业绩或成就存在重大差异。

All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law..

本新闻稿中包含的所有前瞻性声明仅在本新闻稿发布之日起生效。公司不承诺更新这些前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。。

ABOUT LSL PHARMA GROUP INC.

关于LSL PHARMA GROUP INC。

LSL Pharma Group Inc. is an integrated Canadian pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as natural health products in solid dosage forms. For further information, please visit the following website www.groupelslpharma.com..

LSL Pharma Group Inc.是一家综合性加拿大制药公司，专业从事高质量无菌眼科药物以及固体剂型天然保健产品的开发、制造和商业化。欲了解更多信息，请访问以下网站www.groupelslpharma.com。。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

TSX风险交易所及其监管服务提供商（该术语在TSX风险交易所的政策中定义）均不对本版本的充分性或准确性承担责任。

CONTACT : François Roberge, President and Chief Executive Officer Telephone: (514) 664-7700 E-mail: investors@groupelslpharma.com Or Luc Mainville, Executive Vice President & Chief Financial Officer Telephone: (514) 664-7700 Ext. 301 E-mail: lmainville@groupelslpharma.com

联系人：总裁兼首席执行官弗朗索瓦·罗伯格电话：（514）664-7700电子邮件：investors@groupelslpharma.com或执行副总裁兼首席财务官Luc Mainville电话：（514）664-7700分机301电子邮件：lmainville@groupelslpharma.com